Page 58 - Sohini Das

Hard choice for MSME med device makers: Get licence by Oct 1 or shut shop

All Class A and Class B med device makers to switch to licensing regime within; many are dealing with slow pace of govt audits or simply not clearing them

Mankind Pharma files for IPO, could be second largest among pharma firms

The offer for sale is expected to be anywhere between Rs 5000-5500 crore, say sources

The SSI Mantra: India's own surgical robot boasts cheaper price tag

SSI Mantra has already been used for 22 complex procedures at Delhi hospital

India warming up to vast potential of crowd-funding for healthcare

Of the 1.3 million active patients in India, around 890,000 have given consent to be up for adoption

Essential medicines list updated, adds 34 new drugs and drops 26

Medicines to treat diabetes, HIV, TB, contraceptives, hormonal medicines included in National List of Essential Medicines

NLEM 2022: Analysts see no major impact pharma companies' growth

The 2022 revision of the NLEM came after seven years. Most drugs that have been now brought into the NLEM include anti-infectives, anti-diabetics, anesthetics, etc

Essential medicines to get cheaper in India after the release of NLEM

The medicines listed in the NLEM are sold below a price ceiling fixed by the National Pharmaceutical Pricing Authority (NPPA)

Patients' out-of-pocket medical bill spend declined in 2018-19, shows data

The NHA 2018-19 highlighted that the Centre's expenditure on the National Health Mission was Rs 30,578 crore

Pharma body clears Micro Labs of charges of spending Rs 1000 cr on freebies

Indian Pharmaceutical Alliance ethics committee submits report to NPPA

Serum Institute may give India its first adult tuberculosis vaccine

Will be critical to the success of India's drive to eliminate TB by 2025

Crowdfunding under govt's Ni-kshay Mitra comes to the aid of TB eradication

Initiative seeks to involve communities in adopting patients and ensuring proper food for them

Largest Ibuprofen API maker eyes double revenue in next four years

As part of de-risking their business, they have started reducing the share of ibuprofen in their overall turnover, and add more popular products to the portfolio

Bharat Biotech awaits booster dose nod for intranasal vaccine iNCOVACC

Bharat Biotech did not comment on its plans to make this vaccine available for young children

Breast cancer among men slowly on the rise & usually detected late: Doctors

The disease is now being diagnosed in relatively younger men

India's first nasal vaccine for Covid-19 gets DCGI nod for emergency use

Bharat Biotech's iNCOVACC cleared for 2-dose regimen

National Immunisation Mission: How indigenous vaccines can go a long way

The locally developed Ceravac can play a critical role in the efficacy of the National Immunisation Mission

India-made cervical cancer vaccine Ceravac to cost Rs 200-400 per dose

Serum India's product made in collaboration with state-run biotechnology department, expected to bring down prices

Molbio Diagnostics looking to expand test menu on its Truenat platform

The company is also open to raising funds and has been in talks with PE and VC funds for the same

Glenmark Pharma launches Ryaltris nasal spray for allergic rhintis in US

British drugmaker Hikma to distribute Ryaltris while Glenmark will manufacture it

Streamlining trade margins on drugs priced Rs 100 and above likely

Drugs for ailments like chronic kidney disease, some high end antibiotics, anti-virals (anti-infectives), as well as some cancer drugs are likely to be brought under trade margin rationalization first